Prognosis value of central venous oxygen saturation in acute decompensated heart failure  by Gallet, Romain et al.
Archives of Cardiovascular Disease (2012) 105, 5—12
Available  online  at
www.sciencedirect.com
CLINICAL RESEARCH
Prognosis  value  of  central  venous  oxygen  saturation
in acute  decompensated  heart  failure
Valeur  pronostique  de  la  saturation  veineuse  en  oxygène  dans  l’insufﬁsance
cardiaque  aiguë
Romain  Galleta,  Nicolas  Lellouchea,
Laurens  Mitchell-Heggsa,  Belaid  Bouhemadb,
Alexandre  Bensaida,  Jean-Luc  Dubois-Randéa,
Pascal  Guereta,  Pascal  Lima,∗
a Inserm  U955,  department  of  cardiovascular  medicine,  Henri-Mondor  hospital,  AP—HP,
university  hospital  Henri-Mondor,  51,  avenue  de  Lattre-de-Tassigny,  94010  Créteil,  France
b Department  of  anaesthesia  and  critical  care,  AP—HP,  Pitié-Salpêtrière  hospital,  75013  Paris,
France
Received 25  May  2011;  received  in  revised  form  2  October  2011;  accepted  20  October  2011
Available  online  13  January  2012
KEYWORDS
Acute  heart  failure;
Cardiogenic  shock;
Heart  transplant;
Central  venous
oxygen  saturation
Summary
Background.  —  Central  venous  oxygen  saturation  (ScvO2)  provides  an  estimation  of  body  oxygen
consumption/delivery  ratio.  Its  use  has  been  suggested  for  monitoring  treatment  of  patients
admitted  for  acute  decompensated  heart  failure  (ADHF)  but  the  optimal  target  value  has  never
been clearly  reported.
Aims.  —  We  aimed  to  address  the  prognostic  value  of  ScvO2 in  ADHF  requiring  inotrope  support.
Methods.  —  ScvO2 was  prospectively  assessed  in  60  patients  with  ADHF  requiring  inotrope  sup-
port (mean  age  62  ±  16  years;  45  men;  left  ventricular  ejection  fraction  25  ±  7%)  and  was
compared  with  major  adverse  cardiac  events  (MACE),  deﬁned  as  heart  transplantation,  cardiac
assistance  and  death.
Results.  —  MACE  occurred  in  22  (35%)  patients  (14  deaths;  eight  referred  for  heart  trans-
plantation  or  cardiac  assistance).  Admission  ScvO2 (mean  57  ±  13%)  did  not  differ  between
patients with  and  without  MACE.  At  24  hours  ScvO2 (mean  62  ±  7%)  increased  only  in
patients without  MACE  (65  ±  6%  vs.  58  ±  7%;  p  <  0.0001)  and  was  associated  with  urine  out-
put, vena  cava  diameter  and  oxygen  consumption  reduction.  No  correlation  was  observed
Abbreviations: ADHF, acute decompensated heart failure; BP, blood pressure; LV, left ventricular; MACE, major adverse cardiac events;
ScvO2, central venous oxygen saturation; TAPSE, tricuspid annular plane systolic excursion; VO2, organ oxygen consumption.
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between  ScvO2 and  cardiac  output  or  catecholamine  rate.  Multivariable  analysis  showed  that
ScvO2 at  24  hours  remained  an  independent  predictor  of  MACE.  Using  the  optimal  cut-off  of  60%
derived from  receiver  operating  characteristic  curves,  MACE  were  observed  in  81%  of  patients
(17/21) with  ScvO2 ≤  60%  at  24  hours  vs.  13%  (5/39)  with  ScvO2 >  60%  at  24  hours.
Conclusion.  —  In  patients  admitted  for  ADHF  requiring  inotrope  support,  ScvO2 ≤  60%  despite
optimal treatment  is  a  marker  of  poor  outcome  and  might  be  an  indicator  for  considering  more
aggressive  therapy.
©  2011  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Contexte.  —  La  saturation  veineuse  centrale  en  oxygène  (ScvO2)  permet  une  estimation  de
l’adéquation  entre  l’apport  en  oxygène  et  la  consommation  tissulaire.  Son  utilisation  pour  le
monitoring  des  patients  hospitalisés  pour  insufﬁsance  cardiaque  aiguë  est  préconisée  mais  sa
valeur optimale  et  l’inﬂuence  de  ses  variations  sur  le  pronostic  n’ont  jamais  été  étudiées.
Objectifs.  —  L’objectif  est  d’étudier  la  valeur  pronostique  de  la  ScvO2 chez  les  patients  hospi-
talisés pour  insufﬁsance  cardiaque  aiguë  sévère.
Méthodes.  —  La  ScvO2 a  été  recueillie  de  fac¸on  prospective  chez  60  patients  (moyenne
62 ±  16  ans  ;  45  hommes  ;  FEVG  25  ±  7  %)  hospitalisés  pour  une  poussée  d’insufﬁsance  cardiaque
avec nécessité  de  recours  à  un  traitement  inotrope  positif.  Le  critère  de  jugement  inclu-
ait la  survenue  d’évènements  cardiovasculaires  majeurs  (décès,  assistance  ou  transplantation
cardiaque).
Résultats.  —  Un  évènement  est  survenu  chez  22  (35  %)  patients  (14  décès  ;  huit  assistances  ou
transplantation  cardiaque).  Il  n’y  avait  pas  de  différence  concernant  la  ScvO2 à  l’admission
(moyenne  57  ±  13  %)  chez  les  patients  avec  et  sans  évènements.  Après  24  heures  de  traitement,
la ScvO2 (moyenne  62  ±  7  %)  n’augmentait  que  chez  les  patients  sans  évènement  (65  ±  6  %  vs
58 ±  7  %  ;  p  <  0,0001)  et  était  corrélée  à  la  diurèse,  au  diamètre  de  la  veine  cave  inférieure  et
à la  réduction  de  la  consommation  en  oxygène.  La  ScvO2 n’était  ni  corrélée  aux  doses  de  caté-
cholamines  ni  au  débit  cardiaque.  En  analyse  multivariée,  la  ScvO2 restait  associé  au  pronostic.
La survenue  d’un  évènement  était  observé  chez  81  %  (17/21)  des  patients  ayant  une  ScvO2 ≤  60  %
à 24  heures  contre  13  %  (5/39)  lorsque  la  ScvO2 était  inférieure  à  60  %  à  24  heures.
Conclusion.  — Chez  les  patients  hospitalisés  pour  insufﬁsance  cardiaque  aiguë  avec  indication  à
un traitement  inotrope  positif,  une  ScvO2 ≤  60  %  malgré  un  traitement  médical  maximal  est  asso-
cié à  un  mauvais  pronostic.  Cette  valeur  pourrait  faire  considérer  des  options  thérapeutiques
plus agressives.
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ackground
espite  improvements  in  medical  treatment,  acute  decom-
ensated  heart  failure  (ADHF)  with  cardiogenic  shock
emains  associated  with  high  mortality  (50—80%)  [1].  In
linical  practice,  conventional  treatment  includes  cate-
holamine  and  intravenous  diuretic  support,  monitored
y  echocardiography  and  clinical  data.  European  Soci-
ty  of  Cardiology  guidelines  [2]  recommend  the  use  of
entral  venous  oxygen  saturation  (ScvO2)  for  monitoring
hese  patients.  ScvO2 (i.e.  the  oxygen  saturation  from  a
lood  sample  taken  from  the  superior  vena  cava)  provides
n  estimation  of  the  body  oxygen  consumption/delivery
atio.  According  to  Fick’s  equation,  ScvO2 is  determined
y  organ  oxygen  consumption  (VO2;  mL/minute)  and  sup-
ly,  which  depends  on  arterial  oxygen  saturation  (SaO2; %),
aemoglobin  concentration  (Hb;  g/L)  and  cardiac  output
CO):  ScvO2 =  SaO2 —  (VO2/1.34*Hb*CO).In  patients  admitted  for  a  severe  sepsis  or  an  acute
yocardial  infarction,  ScvO2 correlates  with  CO;  low  ScvO2
s  associated  with  poor  prognosis.  The  use  of  ScvO2 appears
uperior  to  clinical  markers  for  monitoring  patients  with
t
l
m
os  droits  réservés.
aemodynamic  instability  and  treatment  adjusted  to  ScvO2
eems  to  provide  a  better  outcome.  However,  the  impact  of
cvO2 in  patients  admitted  for  ADHF  remains  unclear.  The
urpose  of  this  study  was  to  address  the  optimal  target  of
cvO2 for  monitoring  patients  admitted  for  ADHF  requiring
notropic  support.
ethods
opulation study
e  prospectively  included  60  consecutive  patients  (mean
ge  62  ±  16  years;  45  men)  admitted  from  November  2008
o  March  2010  to  the  Intensive  Care  Unit  of  Henri  Mon-
or  University  Hospital  for  ADHF  requiring  inotrope  support.
notropic  support  was  added  when  low  CO  (cardiac  index  less
han  2.2  L/minute  per  meter  square)  or  impaired  left  ven-
ricular  (LV)  ejection  fraction  (<  40%)  was  associated  with
ow  blood  pressure  (BP)  (systolic  BP  <  90  mmHg  or  a  drop  in
ean  BP  of  more  than  30  mmHg)  or  when  persistent  signs
f  low  organ  perfusion  or  oligoanuria  (<  0.5  mL/kg  per  hour)
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Table  1  Patient  characteristics  at  admission.
Event  free  (n  =  38)  MACE  (n  =  22)  p
ScvO2 (%)  57  ±  13  57  ±  14  0.9
SaO2 (%)  96.8  ±  1.9  96.2  ±  3.8  0.4
Lactates  (mmol/L)  2.2  ±  2.0  3.1  ±  3.4  0.2
pH  7.43  ±  0.1  7.41  ±  0.1  0.4
BUN  (mmol/L) 15  ±  9  19  ±  8  0.1
Creatinine  (mol/L)  172  ±  98 194 ±  95 0.4
Bilirubin  (mol/L)  20  ±  11 29 ±  20 0.02
BNP  (pg/L) 3663  ±  3431 6841  ±  7856 0.03
Sodium  (mmol/L)  131  ±  4  129  ±  6  0.2
Potassium  (mmol/L)  4.1  ±  0.8  4.2  ±  0.8  0.5
Haemoglobin  (mg/dL)  12.0  ±  2.0  11.6  ±  2.3  0.4
SBP  (mmHg)  97  ±  16  98  ±  19  0.8
Mean  BP  (mmHg)  72  ±  11  69  ±  13  0.3
Heart  rate  (beats/minute)  84  ±  17  94  ±  20  0.1
Cardiac  index  (L/minute  per  square  meter)  1.8  ±  0.6  2.0  ±  0.9  0.4
LVEF  (%)  26  ±  6  23  ±  9  0.3
EDV  (mL)  208  ±  84  229  ±  95  0.5
ESV  (mL)  156  ±  68  174  ±  81  0.5
E/A  2.7  ±  1.2  2.3  ±  1.1  0.3
SPABP  (mmHg)  45  ±  12  41  ±  8  0.4
TAPSE  (mm)  13  ±  5  15  ±  7  0.3
IVC  (mm)  20.3  ±  3.9  21.1  ±  5.4  0.7
Dobutamine  (g/kg  per  minute)  8.7  ±  4.6  8.6  ±  3.7  NS
Furosemide  (mg/24  hours)  499  ±  408  510  ±  355  NS
Noradrenaline  10  (26)  9  (41)
Rate  (mg/hour)  0.9  ±  0.25  0.9  ±  0.7
Data are mean ± standard deviation or number (%). BNP: brain natriuretic peptide; BP: blood pressure; BUN: blood urea nitrogen; E/A:
early/late diastolic ﬁlling ﬂow; EDF: end-diastolic volume; ESF: end-systolic volume; IVC: inferior vena cava; LVEF: left ventricular
ejection fraction; MACE: major cardiac events; SaO : arterial oxygen saturation; ScvO : central venous oxygen saturation; SBP: systolic
TAPSE
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blood pressure; SPABP: systolic pulmonary artery blood pressure; 
were  reported.  Patients  were  excluded  when  a  palliative
care  decision  was  taken,  when  superior  vena  cava  catheter-
ization  failed  or  when  associated  hypovolaemic  or  septic
shock  was  suspected.  Patients  admitted  for  acute  myocar-
dial  infarction  were  excluded.
Of  the  60  patients  included,  six  had  no  heart  fail-
ure  history  or  known  LV  dysfunction  and  27  (45%)  had
ischaemic  cardiomyopathy.  Admission  LV  ejection  fraction
and  cardiac  index  averaged  25  ±  7%  and  1.9  ±  0.7  L/minute
per  meter  square  (conﬁdence  interval  1.1—2.7),  respec-
tively.  Current  medications  before  hospitalization  included
beta-blocker  therapy  (70%),  angiotensin-converting  enzyme
inhibitors  (79%)  and  oral  loop  diuretics  (84%).  The  study
was  approved  by  our  local  (Henry-Mondor  Hospital)  ethics
committee  and  all  patients  gave  informed  consent  to
participate.
Catecholamine and diuretic infusion
Patients  admitted  for  ADHF  received  standard  care  accord-
ing  to  our  local  protocol,  which  follows  current  guidelines
[2].  All  drugs  were  systematically  delivered  through  a  cen-
tral  venous  catheter  positioned  via  the  jugular  or  subclavian
vein.  Optimal  positioning  of  the  central  venous  catheter
was  conﬁrmed  using  chest  radiography.  The  catheter  had
to  be  at  the  junction  between  the  superior  vena  cava  and
r
a
g
e2
: tricuspid annular plane systolic excursion.
he right  atrium.  The  radiological  landmark  used  to  deter-
ine  the  appropriate  position  was  the  carina.  Intravenous
oop  diuretics  and  vasodilator  drugs  were  ﬁrst  recommended
efore  inotropic  support  when  the  mean  BP  was  more  than
5  mmHg.  In  patients  with  low  BP  and  clinical  signs  of  low
rgan  perfusion  or  with  persistent  oligoanuria,  dobutamine
nfusion  was  recommended  at  a  starting  rate  of  5  g/kg
er  minute.  Dobutamine  was  increased  by  2.5  g/kg  per
inute  to  a  maximum  of  20  g/kg  per  minute,  according  to
he  physician’s  clinical  judgement.  In  patients  with  severe
aemodynamic  instability  or  under  beta-blocker  therapy  at
dmission,  dobutamine  was  started  at  the  rate  of  20  g/kg
er  minute.  Norepinephrine  was  given  if  the  mean  BP
emained  less  than  65  mmHg.  Intravenous  loop  diuretics
ere  systematically  delivered  with  a  starting  dose  adjusted
o  the  severity  of  volume  overload,  renal  function  and  pre-
ious  diuretic  oral  dose  used.  The  diuretic  rate  was  titrated
o  obtain  euvolaemia  assessed  using  clinical  (right  ventricu-
ar  congestion  reduction)  and  echocardiography  data  (vena
ava  dilatation  and  LV  pressure  reduction).  Dobutamine  infu-
ion  was  decreased  progressively  (0.1  g/kg  per  minute  per
our)  when  euvolaemia  and  haemodynamic  stability  were
eached.  No  patient  needed  mechanical  ventilation  support
nd,  when  required,  oxygen  was  delivered  through  an  oxy-
en  mask  to  obtain  an  arterial  oxygen  saturation  greater  or
qual  to  95%.
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Table  2  Patient  characteristics  at  24  hours.
Event  free  (n  =  38)  MACE  (n  =  22)  p
ScvO2 (%)  65  ±  6  58  ±  7  <  0.0001
SaO2 (%)  96.6  ±  2.2  96.8  ±  2.0  0.7
Lactates  (mmol/L)  1.6  ±  0.5  2.0  ±  0.6  0.005
pH  7.46  ±  0.05  7.46  ±  0.05  >  0.9
BUN  (mmol/L) 14  ±  11  17.5  ±  9  0.1
Creatinine  (mol/L)  154  ±  101 175  ±  97 0.4
Bilirubin  (mol/L)  19  ±  10 29  ±  19 0.02
BNP  (pg/L) 3888  ±  4371 5260  ±  3984 0.3
Sodium  (mmol/L)  132  ±  4  129  ±  6  0.02
Potassium  (mmol/L)  3.7  ±  0.7  3.8  ±  0.6  0.4
Haemoglobin  (mg/dL)  12.0  ±  2.2  11.5  ±  2.3  0.4
SBP  (mmHg)  103  ±  15  104  ±  14  >  0.9
Mean  BP  (mmHg)  73  ±  9  73  ±  9  >  0.9
Heart  rate  (beats/minute)  92  ±  19  94  ±  18  0.6
Urine  output  (L)  4.2  ±  1.9  2.9  ±  1.6  0.02
Cardiac  index  (L/minute  per  square  meter)  2.0  ±  0.6  2.1  ±  0.7  0.7
LVEF  (%)  27  ±  6  24  ±  10  0.2
EDV  (mL)  206  ±  91  228  ±  79  0.5
ESV  (mL)  152  ±  73  182  ±  75  0.2
E/A  2.1  ±  1.2  2.5  ±  1.1  0.3
SPABP  (mmHg)  37  ±  11  36  ±  10  >  0.9
TAPSE  (mm)  14  ±  5  13  ±  5  0.4
IVC  (mm)  18.1  ±  5.9  22.3  ±  5.0  0.04
Dobutamine  (g/kg/minute)  8.5  ±  4.3  10.0  ±  2.8  0.1
Furosemide  (mg/24  hours)  348  ±  303  465  ±  325  0.2
Noradrenaline  13  (34)  9  (41)
Rate  (mg/hour)  0.9  ±  0.3  1.7  ±  2.1
Data are mean ± standard deviation or number (%). BNP: brain natriuretic peptide; BP: blood pressure; BUN: blood urea nitrogen; E/A:
early/late diastolic ﬁlling ﬂow; EDF: end-diastolic volume; ESF: end-systolic volume; IVC: inferior vena cava; LVEF: left ventricular
ejection fraction; MACE: major cardiac events; SaO2: arterial oxygen saturation; ScvO2: central venous oxygen saturation; SBP: systolic
blood pressure; SPABP: systolic pulmonary artery blood pressure; TAPSE: tricuspid annular plane systolic excursion.
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Sransthoracic echocardiography
ransthoracic  echocardiography  was  systematically  per-
ormed  at  admission  and  after  24  hours.  CO  was  assessed
sing  the  conventional  pulsed  Doppler  method  positioned
t  the  LV  outﬂow  tract.  LV  volumes  and  ejection  fraction
ere  quantiﬁed  using  Simpson’s  biplane  method.  Early  and
ate  diastolic  ﬁlling  ﬂows  were  assessed  using  conventional
ulsed  Doppler.  Right  ventricular  function  was  quantiﬁed  by
he  amplitude  of  the  tricuspid  annular  plane  systolic  excur-
ion  (TAPSE).  The  inferior  vena  cava  diameter  was  assessed
rom  the  subcostal  view  by  M  mode  during  the  expiration
eriod  [3,4].
aemodynamic monitoring
nvasive  BP  monitoring  was  performed  using  a  radial  arte-
ial  catheter.  BP  and  urine  output  were  monitored  every
our  during  the  ﬁrst  12  hours  and  every  3  hours  thereafter.
cvO2 assessment  was  performed  by  a  standard  gas  analyser
sing  a  blood  sample  taken  from  the  central  venous  catheter.
cvO2 was  assessed  before  and  every  12  hours  after  inotropic
upport  was  initiated.
N
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ylinical outcomes
he  primary  endpoint  was  deﬁned  by  the  occurrence  of
ajor  adverse  cardiac  events  (MACE)  that  included  death,
eart  transplantation  or  cardiac  assistance  during  the
ospitalization  period.  Heart  transplantation  and  cardiac
ssistance  were  indicated  in  eligible  patients  (age  less
han  65  years  without  severe  comorbidity)  with  a  maxi-
al  catecholamine  dose  (dobutamine  20  g/kg  per  minute)
espite  an  optimal  volume  load  or  a  maximal  diuretic
ose  (furosemide  1  g/24  hours);  the  decision  was  made  by
n  expert  committee  that  included  cardiac  surgeons  and
ardiologists  not  involved  in  the  study.  The  French  Trans-
lantation  Agency  (Agence  de  la  Biomédecine)  guidelines  do
ot  include  ScvO2 as  a  criterion  for  patient  referral  for  heart
ransplantation  or  cardiac  assistance.
tatistical analysis
ormally  distributed  continuous  variables  were  expressed
s  mean  ±  standard  deviation  and  nominal  variables  as  per-
entages.  Comparisons  between  patients  with  and  without
ACE  were  done  using  Student’s  t test  or  variance  anal-
sis  for  continuous  variables  and  the  chi-square  test  for
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Figure 1. Changes in central venous oxygen saturation (ScvO2;
mean ± standard error) according to outcome. MACE: major car-
diac events (cardiac assistance, heart transplantation or death).
* p < 0.05 versus admission; † p < 0.05 versus 24 hours; ‡ p < 0.05
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dichotomous  values.  Paired  analysis  was  performed  for
repeated  values.  Multivariable  analysis  by  stepwise  regres-
sion  was  used  to  identify  the  independent  predictor  of
outcome.  For  the  ﬁrst  step,  all  variables  with  p  <  0.1  were
included  in  the  model.  Statistical  difference  was  considered
as  signiﬁcant  when  p  <  0.05.
Results
Admission  dobutamine  and  furosemide  rates  averaged
8.7  ±  4.3  g/kg  per  minute  (range  3—20)  and  529  ±
366  mg/24  hours,  respectively.  Norepinephrine  was  added
in  23  (38%)  patients  with  persistent  low  BP  at  the
rate  of  0.22  ±  0.11  g/kg  per  minute.  Overall,  CO  (3.2  ±
1.3  L/minute  to  3.6  ±  1.2  L/minute;  p  =  0.06),  systolic  BP  and
renal  function  improved  under  treatment  (Tables  1  and  2).
Outcome
During  the  hospitalization  period  (11  ±  12  days),  MACE
occurred  in  22  (37%)  patients.  No  MACE  occurred  in  the
ﬁrst  24  hours.  Deaths  from  refractory  heart  failure  occurred
after  14  ±  15  days  in  14  patients  not  eligible  for  cardiac
assistance  because  of  advanced  age  or  comorbidity  (72  ±  14
years).  Cardiac  assistance  and  heart  transplantation  were
required  in  eight  patients  (46  ±  10  years,  range  35—63)
after  15  ±  8  days  under  catecholamine.  In  patients  with-
out  MACE  (n  =  38),  dobutamine  infusion  was  maintained  for
5  ±  4  days  after  admission  and  successfully  weaned  in  3  ±  3
days.  At  admission,  patients  who  experienced  MACE  had  a
higher  plasma  concentrations  of  bilirubin  (29  ±  20  mol/L
vs.  20  ±  11  mol/L;  p  =  0.02)  and  brain  natriuretic  pep-
tide  (6841  ±  7856  pg/mL  vs.  3663  ±  3431  pg/mL;  p  =  0.03).
At  24  hours,  hyponatraemia  and  plasma  concentrations  of
bilirubin  and  lactate  were  greater  in  the  MACE  group
(Table  2).  Urine  output  was  greater  (4.2  ±  1.9  L  vs.
2.9  ±  1.6  L;  p  =  0.02)  and  the  vena  cava  diameter  was
smaller  (18  ±  6  mm  vs.  22  ±  5  mm;  p  =  0.04)  in  patients
who  did  not  experience  MACE.  In  contrast,  diuretic  and
inotrope  starting  rates  and  cardiac  index  at  admission
(2.0  ±  0.9  L/minute/m2 vs.  1.8  ±  0.5  L/minute/m2)  and  at
24  hours  (2.1  ±  0.7  L/minute/m2 vs.  2.0  ±  0.6  L/minute/m2)
did  not  differ  according  to  outcome.
Admission ScvO2 and outcome
Admission  ScvO2 before  dobutamine  infusion  was  available
in  49  (82%)  patients  and  averaged  57  ±  13%  (range  28—77;
Fig.  1).  Admission  ScvO2 ≤  60%  was  observed  in  57%  (28/49)
of  patients,  without  difference  between  those  with  and
without  MACE  (61%  vs.  55%).  Admission  ScvO2 correlated
with  sodium  (r  =  0.33;  p  =  0.02)  and  the  plasma  concentra-
tion  of  brain  natriuretic  peptide  (r  =  —0.31;  p  =  0.02)  but
not  with  CO,  haemoglobin  concentration  and  arterial  oxygen
saturation.
Changes in ScvO2 and outcomeAt  24  hours,  ScvO2 increased  in  patients  without  MACE
but  remained  unchanged  in  those  who  experienced
MACE  (Fig.  1).  Percentages  of  MACE  according  to  ScvO2
F
tersus before catecholamine weaning.
uartiles  are  presented  in  Fig.  2.  Using  receiver  operating
haracteristic  curves,  the  optimal  cut-off  value  for  pre-
icting  MACE  was  60%  (Fig.  3;  Table  3).  In  patients  with
cvO2 >  60%  at  24  hours  (n  =  39),  dobutamine  was  safely  with-
rawn  in  87%  (34/39)  within  3  ±  3  days.  After  dobutamine
ithdrawal,  ScvO2 slightly  decreased  (68  ±  6%  vs.  65  ±  8%;
 =  0.03;  Fig.  1).
In  contrast,  when  ScvO2 was  less  or  equal  to  60%  at
4  hours  (n  =  21),  MACE  occurred  in  81%  (17/21)  of  patients.
n  addition,  the  last  ScvO2 was  less  or  equal  to  60%
n  90%  (19/21)  of  patients  who  experienced  MACE.  No
ifference  was  observed  between  death  and  cardiac  assis-
ance  or  heart  transplantation.  By  multivariable  analysis
Table  4),  ScvO2, urine  output  and  bilirubin  concentration
ere  independent  predictors  of  MACE.  Area  under  receiver
perating  characteristic  curves  for  these  variables  are  shown
n  Fig.  3.igure 2. Percentage of major cardiac events according to cen-
ral venous oxygen saturation (ScvO2) quartiles.
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Figure 3. Receiver operating characteristic curves for predicting major
output, lactate and bilirubin at 24 hours. AUC: area under the curve.
Table  3  Sensitivity,  speciﬁcity,  predictive  positive  val-
ues  and  negative  predictive  values  according  to  central
venous  oxygen  saturation  cut-off  values.
ScvO2 (%)  Sensitivity  (%)  Speciﬁcity  (%)  PPV  (%)  NPV  (%)
57  64  95  88  82
60 77  89  81  87
63 86 58  54  88
NPV: negative predictive value; PPV: predictive positive value;
ScvO2: central venous oxygen saturation.
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8 cardiac events for central venous oxygen saturation (ScvO2), urine
elationship between ScvO2 and other
aemodynamic variables
atients  with  ScvO2 >  60%  at  24  hours  had  a  greater  urine
utput  (4.0  ±  0.3  L  vs.  3.0  ±  0.3  L;  p  =  0.04)  and  vena  cava
iameter  reduction  (—18%  [—4  ±  6  mm]  vs  +  15%  [2  ±  4  mm];
 =  0.007)  than  patients  with  ScvO2 ≤  60%,  while  Fick’s
quation-derived  VO2 was  lower  (102  ±  37  mL/minute  per
quare  meter  vs.  133  ±  48  mL/minute  per  square  meter;
 =  0.02).  In  contrast,  no  difference  was  observed  between
cvO2 and  cardiac  index  (2.0  ±  0.6  L/minute  per  square
eter  vs.  1.9  ±  0.7  L/minute  per  square  meter;  p  =  0.1
or  24-hour  ScvO2 >  60%  and  ≤  60%,  respectively)  or  cat-
cholamine  rate  (dobutamine  9.1  ±  3.9  g/kg/minute  vs.
.7  ±  4.3  g/kg  per  minute;  p  =  0.3  for  24-hour  ScvO2 >  60%
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Table  4  Predictor  outcome  in  acute  decompensated  heart  failure  with  cardiogenic  shock.
Univariate  analysis  Multivariable  analysis
No  MACE  (mean  ±  SD)  MACE  (mean  ±  SD)  p  OR  95%  CI  p
ScvO2 at  24  hours  (per  %)  65 ±  6  58  ±  7  <  0.0001  0.80  0.68—0.92  0.003
Urine  output  (per  L) 4.2 ± 1.9  2.9 ±  1.6  0.02  0.50  0.28—0.90 0.02
Bilirubin  at  24  hours  (per  10  mol/L)  19  ±  10  29  ±  19  0.02  2.8  1.3—6.2  0.01
Lactates  at  24  hours  (per  mmol/L)  1.6  ±  0.5  2.0  ±  0.6  0.005  5.6  0.8—37.8  0.08
Sodium  at  24  hours  (per  mmol/L)  132  ±  4  129  ±  6  0.02
IVC  at  24  hours  (per  mm)  18  ±  6  22  ±  5  0.04
CI: conﬁdence interval; IVC: inferior vena cava; MACE: major cardiac events; OR: odds ratio; ScvO2: central venous oxygen saturation;
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SSD: standard deviation.
and  ≤  60%,  respectively).  In  addition,  we  did  not  observe  a
signiﬁcant  association  between  ScvO2 and  the  TAPSE  value
at  admission  and  24  hours  after  treatment.
Discussion
Prognosis  of  ADHF  with  cardiogenic  shock  remains  poor
despite  improvement  in  medical  treatments.  Management  of
patients  with  uncompensated  heart  failure  and  cardiogenic
shock  is  conventionally  based  on  the  diagnosis  and  treat-
ment  of  underlying  causes  and  on  symptomatic  treatment
with  diuretics  and  inotrope  support.  The  monitoring  of  these
drugs  relies  on  clinical  and  echocardiography  data  while
ScvO2 is  poorly  used  because  its  assessment  requires  invasive
catheter  positioning  and  no  study  has  clearly  addressed  its
optimal  target  in  ADHF.  The  present  study  demonstrates  that
an  early  increase  in  ScvO2 >  60%  at  24  hours  is  strongly  cor-
related  with  a  favourable  outcome.  MACE  occurred  mostly
(81%)  in  patients  with  ScvO2 that  remained  ≤  60%,  while
event-free  survival  with  successful  dobutamine  weaning  was
observed  in  88%  of  patients  with  ScvO2 >  60%  at  24  hours.
Importantly,  changes  in  ScvO2 appear  to  be  more  associated
with  a  greater  reduction  in  vena  cava  diameter  and  urine
output  (which  are  indirect  markers  of  response  to  diuretic
treatment  and  venous  congestion)  than  with  the  increase  in
CO,  as  commonly  believed.
The  usefulness  of  ScvO2 for  monitoring  shock  has  been
addressed  in  septic  shock,  with  an  impressive  decrease  in
mortality  with  ScvO2-adjusted  treatment  [5].  The  prognos-
tic  value  of  ScvO2 has  also  been  addressed  in  different
critical  haemodynamic  situations  [5—9]. In  acute  coronary
syndromes,  venous  blood  oxygen  saturation  has  been  used
to  identify  patients  at  risk  of  heart  failure  or  cardiogenic
shock  [9,10]. Few  studies  have  clearly  addressed  the  prog-
nostic  value  of  ScvO2 in  ADHF,  despite  current  guidelines
recommending  its  use  for  monitoring  drug  therapy  and  stud-
ies  suggesting  its  superior  sensitivity  over  clinical  markers
[11,12].  ScvO2 reﬂects  the  balance  between  organ  oxy-
gen  consumption  and  supply.  A  decrease  in  ScvO2 may  be
observed  when  oxygen  consumption  increases  or  when  oxy-
gen  supply  is  inadequate  (anaemia,  hypoxaemia  or  low  CO).
In  cardiogenic  shock,  the  decrease  in  ScvO2 is  commonly
attributed  to  an  inadequate  oxygen  delivery  related  to  low
CO  [9].  ScvO2 has  been  suggested  for  monitoring  CO  to  guide
H
p
catecholamine  titration.  However,  this  approach  is  under
ebate  and  several  studies  have  reported  a  lack  of  cor-
elation  between  ScvO2 and  CO  in  advanced  heart  failure
atients  [13—15]. Our  results  are  consistent  with  these  stud-
es  and  we  believe  that  the  correlation  between  changes
n  ScvO2 during  ADHF  and  CO  may  be  hidden  by  the  oxy-
en  consumption  reduction  related  to  a  decrease  in  organ
ongestion.  This  hypothesis  is  supported  by  the  correla-
ion  observed  between  changes  in  ScvO2 and  urine  output,
ena  cava  diameter  and  VO2 reduction.  However,  we  cannot
xclude  that  our  data  may  be  biased  by  the  limitation  of
chocardiography  in  the  assessment  of  CO.
Bilirubin,  which  reﬂects  the  severity  of  venous  conges-
ion  in  ADHF,  has  been  found  to  be  strongly  associated  with
 worse  outcome  in  our  study  and  by  others  [16]. This
nderlines  the  deleterious  impact  of  overload,  as  reported
y  Mullens  et  al.  [17], who  showed  that  cardiorenal  syn-
rome  in  ADHF  is  not  related  to  CO  reduction,  as  commonly
elieved,  but  mainly  to  the  severity  of  venous  congestion.
onsistently,  indirect  overload  reduction  markers  (urine  out-
ut  and  vena  cava  diameter  reduction)  correlated  with  a
avourable  outcome  and  improvement  in  ScvO2, probably
hrough  oxygen  consumption  reduction.  This  hypothesis  is
upported  by  Lautt  et  al.,  who  showed  that  venous  conges-
ion  induced  by  vena  cava  occlusion  (cat  model)  reduces
epatic  blood  ﬂow  but  is  compensated  by  an  increase  in
xygen  extraction  [18]. The  superiority  of  venous  conges-
ion  reduction  over  CO  restoration  has  been  mainly  reported
n  ADHF  patients  with  preserved  BP  and  might  explain  the
ack  of  beneﬁcial  effect  of  dobutamine  in  these  patients
19,20].  In  cardiogenic  shock,  the  use  of  inotropic  drugs
annot  be  avoided  because  of  the  low  BP  and  persistent
nuria  despite  adequate  diuretic  support.  However,  the  rate
nd  target  of  catecholamine  infusion  remain  unclear.  Our
tudy  demonstrates  that  venous  congestion  reduction  may
e  more  important  than  CO  restoration  and  suggests  that
cvO2 should  be  used  to  monitor  both  catecholamine  and
iuretic  rates  in  order  to  ensure  a  favourable  response  to
iuretic  and  inotropic  support.
tudy limitationsaemodynamic  monitoring  of  cardiogenic  shock  is  routinely
erformed  by  echocardiography  and  not  by  a  Swan-Ganz
atheter  [21]. This  may  limit  the  interpretation  of  LV  load
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ressure  given  the  limited  accuracy  of  echocardiography
arkers  in  this  population  [22]. However,  the  use  of  the
ena  cava  diameter  provides  a  fair  assessment  of  venous
ongestion  and  right  atrial  pressure.  In  addition,  despite  an
xisting  correlation,  venous  blood  oxygen  saturation  from
he  superior  vena  cava  and  pulmonary  artery  may  differ;
hese  results  should  therefore  be  validated  for  venous  oxy-
en  saturation  from  pulmonary  artery.  Finally  this  study
as  done  on  a  small  sample  of  patients  and  its  results
 especially  the  60%  cut-off  value  —  need  to  be  validated
n  larger  populations.
onclusion
n  ADHF  requiring  inotrope  support,  improvement  in  ScvO2
o  more  than  60%  at  24  hours  appears  to  correlate  with  event
ree  outcome.  ScvO2 improvement  seems  to  be  more  related
o  vena  cava  diameter  reduction  and  urine  output  than  to
O  improvement.  In  patients  admitted  for  ADHF  with  cardio-
enic  shock,  ScvO2 ≤  60%  at  24  hours  despite  maximal  doses
f  catecholamine  and  diuretic  may  be  an  indicator  for  the
onsideration  of  more  aggressive  therapeutic  options.
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